The Association for Value-Based Cancer Care (AVBCC) in New York
Key Opinion Leader Session 27: Cell and Gene Therapy Market Updates
Cell and Gene Therapy innovation is rapidly entering the US marketplace and the pipelines are full. The promise of regenerative medicine in cancer is exciting, but the delivery costs are frightening to healthcare payers and patients alike. This panel will discuss how to bring the innovation and value these technologies are delivering to the cancer care marketplace, including their fit in value-based contracting equations. As the market shifted from fee-for-service to value-based payment, how do we make sure that advanced therapies have the appropriate value-based endpoints to make sure the patients get the right drugs and the drugs get reimbursed? A key topic is risk—how do we manage the risk of these value-based agreements? Every manufacturer says they want to do value-based care. But when you ask what that looks like, there’s often a long silence. What does value-based care look like to our panelists? In 2020, CMS introduced a new DRG for CAR-Ts, and made further updates to its policy proposals in 2021. Are payment approaches evolving quickly enough? What other innovations need to happen, and what new types of information data are needed, to enable sustainable payments for these innovative therapies.
Joe DePinto, Chief Commercial Officer, Vineti
· Bruce Feinberg, DO, Vice President, Chief Medical Officer – Cardinal Health Specialty Solutions
· Erin Satterwhite, Founder, President, and GM – Optum Frontier
· Blasine Penkowski, Chief Strategic Customer Officer, Janssen